The private placement is for 21,000 units at
These funds will be used for the Company's 2014 growing trials on a wide range of crops and to continue research and development activities.
This news release contains certain statements that may be deemed "forward-looking" statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although TerraBioGen believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of TerraBioGen's management on the date the statements are made. Except as required by law, TerraBioGen undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN
FOR FURTHER INFORMATION PLEASE CONTACT:
Blair HeffelfingerPresident & CEO TerraBioGen Technologies Inc.email@example.com (604) 444-1023 ext 316 (604) 444-1043 fax Bob NowellCFO & Corporate Secretary TerraBioGen Technologies Inc.firstname.lastname@example.org (604) 444-1023 ext 306 (604) 444-1043 fax Source: TerraBioGen Technologies Inc.